Xenon Pharmaceuticals Inc. (XENE): Price and Financial Metrics

Xenon Pharmaceuticals Inc. (XENE): $38.83

-0.06 (-0.15%)

POWR Rating

Component Grades













Add XENE to Watchlist
Sign Up

Industry: Biotech



in industry


  • XENE scores best on the Value dimension, with a Value rank ahead of 45.52% of US stocks.
  • XENE's strongest trending metric is Growth; it's been moving down over the last 177 days.
  • XENE ranks lowest in Growth; there it ranks in the 5th percentile.

XENE Stock Summary

  • With a price/sales ratio of 184.39, XENON PHARMACEUTICALS INC has a higher such ratio than 98.4% of stocks in our set.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at 1.03 for XENON PHARMACEUTICALS INC; that's greater than it is for just 6.4% of US stocks.
  • As for revenue growth, note that XENE's revenue has grown -33.65% over the past 12 months; that beats the revenue growth of merely 5.86% of US companies in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to XENON PHARMACEUTICALS INC are MRUS, AFMD, RAPT, TSVT, and FGEN.
  • Visit XENE's SEC page to see the company's official filings. To visit the company's web site, go to www.xenon-pharma.com.

XENE Valuation Summary

  • XENE's price/sales ratio is 184.7; this is 9135% higher than that of the median Healthcare stock.
  • XENE's EV/EBIT ratio has moved down 29.8 over the prior 98 months.

Below are key valuation metrics over time for XENE.

Stock Date P/S P/B P/E EV/EBIT
XENE 2022-12-02 184.7 3.2 -21.6 -20.5
XENE 2022-12-01 175.4 3.1 -20.5 -19.4
XENE 2022-11-30 175.1 3.1 -20.5 -19.4
XENE 2022-11-29 172.8 3.0 -20.2 -19.1
XENE 2022-11-28 173.2 3.0 -20.2 -19.2
XENE 2022-11-25 165.3 2.9 -19.3 -18.2

XENE Growth Metrics

    Its 5 year price growth rate is now at 66.11%.
  • The 4 year price growth rate now stands at 66.11%.
  • Its 3 year net cashflow from operations growth rate is now at -91.12%.
XENE's revenue has moved up $6,342,000 over the prior 33 months.

The table below shows XENE's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 13.171 -86.408 -112.756
2022-06-30 21.163 -71.013 -90.689
2022-03-31 22.845 -67.222 -81.119
2021-12-31 18.437 -69.502 -77.087
2021-09-30 19.85 -61.906 -63.985
2021-06-30 18.28 -58.053 -57.507

XENE's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • XENE has a Quality Grade of D, ranking ahead of 7.55% of graded US stocks.
  • XENE's asset turnover comes in at 0.077 -- ranking 283rd of 681 Pharmaceutical Products stocks.
  • ADMP, ACUR, and ELTP are the stocks whose asset turnover ratios are most correlated with XENE.

The table below shows XENE's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.077 1 -0.353
2021-03-31 0.132 1 -0.233
2020-12-31 0.154 1 -0.194
2020-09-30 0.153 1 -0.197
2020-06-30 0.157 1 -0.237
2020-03-31 0.094 1 -0.381

XENE Price Target

For more insight on analysts targets of XENE, see our XENE price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $27.88 Average Broker Recommendation 1.17 (Strong Buy)

XENE Stock Price Chart Interactive Chart >

Price chart for XENE

XENE Price/Volume Stats

Current price $38.83 52-week high $41.39
Prev. close $38.89 52-week low $23.26
Day low $38.35 Volume 254,400
Day high $39.30 Avg. volume 448,612
50-day MA $35.77 Dividend yield N/A
200-day MA $33.33 Market Cap 2.43B

Xenon Pharmaceuticals Inc. (XENE) Company Bio

Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing differentiated therapeutics for orphan indications in Canada. The company was founded in 1996 and is based in Burnaby, Canada.

XENE Latest News Stream

Event/Time News Detail
Loading, please wait...

XENE Latest Social Stream

Loading social stream, please wait...

View Full XENE Social Stream

Latest XENE News From Around the Web

Below are the latest news stories about XENON PHARMACEUTICALS INC that investors may wish to consider to help them evaluate XENE as an investment opportunity.

Xenon Pharmaceuticals Provides Updates on Proprietary Neurology Pipeline Programs at the Annual Meeting of the American Epilepsy Society (AES 2022)

Company Presents Additional Positive Data from Open Label Extension of Phase 2b ‘X-TOLE’ Clinical Trial for Focal Onset Seizures XEN1101 Phase 3 Program to be Showcased at Scientific Exhibit Taking Place on Sunday, December 4, 2022 BURNABY, British Columbia, Dec. 02, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced it will provide updates on its proprietary, neurology programs at the Annual Meeting of the American E

Yahoo | December 2, 2022

Xenon Pharmaceuticals to Present at the Bank of America Securities Biotech SMID Cap Conference 2022

BURNABY, British Columbia, Nov. 30, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that management will participate in one-on-one investor meetings and a fireside chat presentation at the Bank of America Securities Biotech SMID Cap Conference 2022 taking place virtually from December 7-8, 2022. Fireside Chat/Company Presentation Details: Date:Wednesday, December 7, 2022Time:1:10 pm Eastern Time (10:10 am Pacific T

Yahoo | November 30, 2022

Xenon Pharmaceuticals Stock Scores Rising Relative Strength Upgrade

Xenon Pharmaceuticals stock had its Relative Strength (RS) Rating upgraded from 89 to 92 Tuesday. Is Xenon Pharmaceuticals Stock A Buy? Xenon Pharmaceuticals stock is building a consolidation with a 41.49 entry.

Yahoo | November 29, 2022

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Analysts Just Trimmed Their Revenue Forecasts By 10%

Market forces rained on the parade of Xenon Pharmaceuticals Inc. ( NASDAQ:XENE ) shareholders today, when the analysts...

Yahoo | November 12, 2022

Xenon Pharmaceuticals to Participate in Upcoming Investor Conferences

BURNABY, British Columbia, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that Ian Mortimer, Xenon’s President and Chief Executive Officer, along with Sherry Aulin, Xenon’s Chief Financial Officer, will host fireside chat presentations and participate in one-on-one meetings at the following investor conferences: Guggenheim 4th Annual Immunology and Neurology Day on Monday, November 14, 2022 with a firesid

Yahoo | November 9, 2022

Read More 'XENE' Stories Here

XENE Price Returns

1-mo 8.77%
3-mo 3.22%
6-mo 30.83%
1-year 57.02%
3-year 178.35%
5-year 1,552.34%
YTD 24.30%
2021 103.12%
2020 17.32%
2019 107.77%
2018 123.36%
2017 -63.31%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.7352 seconds.